CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Inclusion Criteria

• •1. Diagnosed of AML according to the World Health Organization (WHO) classification.
• •2. All patients should aged 18 to 65 years.
• •3. Diagnosed of relapsed and refractory AML, according to The guidelines for diagnosis and treatment of relapse /refractory acute myelogenous leukemia in China（2023）
• •4. Diagnostic criteria for relapsed AML: Leukemia cells reappear in the peripheral blood or primitive cells in the bone marrow ≥ 5% (excluding other reasons such as bone marrow regeneration after consolidation chemotherapy) after CR, or leukemia cell infiltration appears outside the marrow.
• •5. Diagnostic criteria for refractory AML: The newly diagnosed patients who failed to respond to two courses of standard treatment; Patients who relapsed within 12 months after consolidation intensive therapy; Patients who relapsed after 12 months and failed to respond to conventional chemotherapy; Patients with two or more recurrences; Patients with persistent extramedullary leukemia.
• •6. The score of Eastern Cooperative Oncology Group (ECOG) is 0-2.
• •7. Renal function: creatinine clearance rate ≥ 30ml/min.
• •8. Liver function: ALT\<5 times normal value, bilirubin\<3 times normal value.
• •9. Predicted survival ≥ 3 months.
• •10. Able to accept oral Venetoclax.
• •11. Sign an informed consent form and be able to understand and follow the procedures required by this protocol.